Irsogladine

Irsogladine
  • CAS No.:57381-26-7

Important Notice

  1. This product is a chemical product/pharmaceutical intermediate. It is not a drug, an active pharmaceutical ingredient (API), or a pharmaceutical-grade material. It has not been granted a drug approval number or a Chemical Drug Substance Approval Notice, has not passed drug-related review and approval, and is not manufactured, tested, or released in accordance with pharmaceutical GMP.
  2. This product is intended solely for non-clinical research, process development, quality studies, further chemical processing, or chemical synthesis. It must not be used in drug-product manufacturing, clinical trials, clinical diagnosis, or administration to humans or animals, or be sold, used as an input, submitted for regulatory filing, or released as an API or pharmaceutical material.
  3. The purchaser must not use this product, or supply it to another party, for personal consumption, sports or fitness, weight loss, health supplements, food, or animal feed.
Other grades of this product :
Irsogladine Basic information
Product Name:Irsogladine
Synonyms:5-triazine-2,4-diamine,6-(2,5-dichlorophenyl)-3;6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine;2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine;Irsogladin;Irsogladine,2,4-DiaMino-6-(2,5-dichlorophenyl)-1,3,5-triazine;IRSOGLADINE;Irsogladine free base;2',5'-Dichlorobenzoguanamine
CAS:57381-26-7
MF:C9H7Cl2N5
MW:256.09
EINECS:
Product Categories:Active Pharmaceutical Ingredients;pharmaceutical intermediates;Inhibitors
Mol File:57381-26-7.mol
Irsogladine Chemical Properties
Melting point 268-269°C
Boiling point 552.2±60.0 °C(Predicted)
density 1.572
storage temp. Keep in dark place,Inert atmosphere,Room temperature
solubility insoluble in H2O; insoluble in EtOH; ≥12.80 mg/mL in DMSO
form solid
pka3.88±0.10(Predicted)
CAS DataBase Reference57381-26-7(CAS DataBase Reference)
Safety Information
MSDS Information
Irsogladine Usage And Synthesis
Biological Activityirsogladine is a pde4 inhibitor and muscarinic acetylcholine receptor binder.irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (p < 0.02, p < 0.001), in tpa-deficient mic

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Read the full Disclaimer
Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye